Tasly Pharmaceutical Group Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000001C81
CNY
13.63
-0.52 (-3.67%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

13.67 M

Shareholding (Jun 2017)

FII

0.02%

Held by 1 FIIs

DII

99.98%

Held by 0 DIIs

Promoter

0.00%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Poor long term growth as Net Sales has grown by an annual rate of -9.48% and Operating profit at -2.22% over the last 5 years

 
2

Negative results in Dec 25

3

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CNY 22,001 Million (Large Cap)

stock-summary
P/E

24.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.79%

stock-summary
Debt Equity

-0.21

stock-summary
Return on Equity

8.47%

stock-summary
Price to Book

1.77

Revenue and Profits:
Net Sales:
1,926 Million
(Quarterly Results - Dec 2025)
Net Profit:
69 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.09%
0%
-11.09%
6 Months
-15.81%
0%
-15.81%
1 Year
-9.79%
0%
-9.79%
2 Years
-16.99%
0%
-16.99%
3 Years
-8.89%
0%
-8.89%
4 Years
-7.09%
0%
-7.09%
5 Years
0.81%
0%
0.81%

Tasly Pharmaceutical Group Co., Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
-9.48%
EBIT Growth (5y)
-2.22%
EBIT to Interest (avg)
15.07
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.59
Tax Ratio
16.92%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.02%
ROCE (avg)
9.92%
ROE (avg)
10.17%

Valuation key factors

Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.90
EV to EBIT
19.44
EV to EBITDA
13.50
EV to Capital Employed
2.12
EV to Sales
2.53
PEG Ratio
NA
Dividend Yield
3.39%
ROCE (Latest)
10.91%
ROE (Latest)
7.88%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2017stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -4.78% vs -9.44% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is -66.07% vs -55.69% in Sep 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,925.80",
          "val2": "2,022.50",
          "chgp": "-4.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "313.80",
          "val2": "371.70",
          "chgp": "-15.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "5.40",
          "val2": "7.30",
          "chgp": "-26.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "130.70",
          "val2": "-14.40",
          "chgp": "1,007.64%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "68.80",
          "val2": "202.80",
          "chgp": "-66.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "101.20%",
          "val2": "125.00%",
          "chgp": "-2.38%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is -3.17% vs -2.03% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 23.54% vs -15.49% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "8,150.10",
          "val2": "8,416.60",
          "chgp": "-3.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,824.70",
          "val2": "1,934.80",
          "chgp": "-5.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "34.00",
          "val2": "64.80",
          "chgp": "-47.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "104.30",
          "val2": "-329.70",
          "chgp": "131.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,061.30",
          "val2": "859.10",
          "chgp": "23.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "166.90%",
          "val2": "170.20%",
          "chgp": "-0.33%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
1,925.80
2,022.50
-4.78%
Operating Profit (PBDIT) excl Other Income
313.80
371.70
-15.58%
Interest
5.40
7.30
-26.03%
Exceptional Items
130.70
-14.40
1,007.64%
Consolidate Net Profit
68.80
202.80
-66.07%
Operating Profit Margin (Excl OI)
101.20%
125.00%
-2.38%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is -4.78% vs -9.44% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is -66.07% vs -55.69% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
8,150.10
8,416.60
-3.17%
Operating Profit (PBDIT) excl Other Income
1,824.70
1,934.80
-5.69%
Interest
34.00
64.80
-47.53%
Exceptional Items
104.30
-329.70
131.63%
Consolidate Net Profit
1,061.30
859.10
23.54%
Operating Profit Margin (Excl OI)
166.90%
170.20%
-0.33%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is -3.17% vs -2.03% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 23.54% vs -15.49% in Dec 2024

stock-summaryCompany CV
About Tasly Pharmaceutical Group Co., Ltd. stock-summary
stock-summary
Tasly Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available